BRIEF published on 11/22/2024 at 07:05, 1 year 1 month ago SoftwareOne Finalizes CHF 70 Million Share Buyback Initiative Share Buyback Shareholder Approval SoftwareOne SIX Swiss Exchange Cloud Solutions
BRIEF published on 11/22/2024 at 07:05, 1 year 1 month ago SoftwareOne finalise son programme de rachat d'actions pour un montant de 70 millions de francs suisses Rachat D'actions Solutions Cloud Approbation Des Actionnaires LogicielOne Bourse Suisse SIX
BRIEF published on 11/22/2024 at 07:05, 1 year 1 month ago First Berlin Raises beaconsmind AG Price Target Amid Strategic Acquisitions Acquisitions Price Target SaaS Solutions Beaconsmind AG First Berlin
BRIEF published on 11/22/2024 at 07:05, 1 year 1 month ago First Berlin relève son objectif de cours pour beaconsmind AG dans le cadre d'acquisitions stratégiques Acquisitions Solutions SaaS Objectif De Prix Beaconsmind AG Premier Berlin
BRIEF published on 11/22/2024 at 06:50, 1 year 1 month ago Komax Group's Strategic Progress Amidst Market Challenges Operational Efficiency Market Expansion Revenue Targets China Market Komax Strategy
BRIEF published on 11/22/2024 at 06:50, 1 year 1 month ago Progrès stratégique du groupe Komax face aux défis du marché Efficacité Opérationnelle Objectifs De Revenus Marché Chinois Expansion Du Marché Stratégie Komax
BRIEF published on 11/22/2024 at 00:05, 1 year 1 month ago Gratomic Provides Update on Aukam Graphite Mine and Board Changes Graphite Supply Gratomic Aukam Graphite Mine Hermanus Manuel Silver Kobus La Grange
BRIEF published on 11/22/2024 at 00:05, 1 year 1 month ago Gratomic fournit des informations actualisées sur la mine de graphite d'Aukam et les changements au sein du conseil d'administration Approvisionnement En Graphite Gratomique Hermanus Manuel Silver Kobus La Grange Mine De Graphite D'Aukam
BRIEF published on 11/21/2024 at 22:10, 1 year 1 month ago Protagonist Therapeutics Nominates PN-881 for Immune-Mediated Skin Disorders Protagonist Therapeutics IL-17 Antagonist PN-881 Skin Diseases Phase I Trials
BRIEF published on 11/21/2024 at 22:10, 1 year 1 month ago Protagonist Therapeutics nomme le PN-881 pour le traitement des troubles cutanés à médiation immunitaire Thérapeutique Protagoniste Antagoniste De L'IL-17 PN-881 Maladies De La Peau Essais De Phase I
Published on 01/20/2026 at 08:00, 35 minutes ago Grande Portage Resources Receives Approval for 2026 Plan of Operations (Drill Permit) from the US Forest Service
Published on 01/20/2026 at 01:10, 7 hours 25 minutes ago Kalo Gold Announces Closing of Second and Final Tranche of Life Offering and Concurrent Private Placement for Total Gross Proceeds of $12.45 Million to Advance the Vatu Aurum Project
Published on 01/20/2026 at 00:35, 8 hours ago Kidoz Welcomes France’s Proposed Under-15 Social Media Ban
Published on 01/20/2026 at 00:00, 8 hours 35 minutes ago RE Royalties Announces Annual Grant of Stock Options and Restricted Share Units
Published on 01/19/2026 at 22:55, 9 hours 40 minutes ago Organto Foods Inc. Implements Early Warrant Exercise Incentive Program
Published on 01/20/2026 at 08:05, 30 minutes ago Misurata Free Zone Authority Signs $2.7 billion Landmark PPP to Transform Misurata Free Zone Port into a leading Mediterranean Gateway and Transhipment Hub
Published on 01/20/2026 at 08:00, 35 minutes ago Cairn Homes Plc: Trading Update for the Year Ended 31 December 2025
Published on 01/20/2026 at 07:45, 50 minutes ago Le projet de plan de continuation de REALITES obtient un très fort soutien de ses créanciers et actionnaires en vue de l’audience du 4 février 2026 au Tribunal de Commerce de Nantes
Published on 01/20/2026 at 07:30, 1 hour 5 minutes ago Gimv leidt een Series B investeringsronde van EUR 51 miljoen in Exciva voor verdere ontwikkeling van een innovatieve Alzheimerbehandeling
Published on 01/20/2026 at 07:30, 1 hour 5 minutes ago Gimv leads € 51 million Series B investment round in Exciva to advance innovative Alzheimer’s therapy
Published on 01/20/2026 at 07:30, 1 hour 5 minutes ago Gimv leads € 51 million Series B investment round in Exciva to advance innovative Alzheimer’s therapy
Published on 01/19/2026 at 17:45, 14 hours 50 minutes ago Calendrier de communication financière 2026
